Document is current
Any future updates will be listed below
-
Authors
Rudisile, S.
Gosewisch, A.
Wenter, V.
Unterrainer, M.
Böning, G.
Gildehaus, F. J.
Fendler, W. P.
Auernhammer, C. J.
Spitzweg, C.
Bartenstein, P.
Todica, A.
Ilhan, H. https://orcid.org/0000-0003-0409-1942
-
Funding
Funding for this research was provided by:
Kuhbier-Langewiesche Foundation (not applicable)
- License Information
-
More Information
Article History
Received: 29 March 2019
Accepted: 30 July 2019
First Online: 8 August 2019
Ethics approval and consent to participate
: This retrospective analysis was performed in compliance with the principles of the Declaration of Helsinki and its subsequent amendments and was approved by the local Ethics Committee of the Medical Faculty of the LMU Munich (approval number 19–027). The requirement to obtain written informed consent was waived due to the retrospective design with irreversibly anonymized patient data prior to the evaluation.
: Not applicable.
: HI is an advisory board member of Bayer, received research funding from Novartis and speaker honoraria from Bayer and Ipsen. CA has received research contracts from Ipsen, Novartis, and ITM Solucin, lecture honorarium from Ipsen, Novartis, and Falk Foundation, and advisory board honorarium from Novartis. CS has received research grants from Novartis, lecture honoraria from Ipsen and Novartis, and advisory board honoraria from Ipsen, Novartis, and Pfizer. All other authors declare no competing interests.
